Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VRDN Viridian Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VRDN
Price (delayed)
$12.39
Market cap
$1.01B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.13
Enterprise value
$915.4M
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal
Highlights
VRDN's gross profit is up by 4.9% YoY
VRDN's revenue is up by 4.9% YoY
VRDN's quick ratio is up by 26% since the previous quarter but it is down by 20% year-on-year
The equity fell by 10% QoQ but it rose by 3.8% YoY
The net income has contracted by 41% YoY and by 14% from the previous quarter
Viridian Therapeutics's EPS has decreased by 8% YoY
Key stats
What are the main financial stats of VRDN
Market
Valuations
Earnings
Shares outstanding
81.59M
Market cap
$1.01B
Enterprise value
$915.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
3,337.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,031.11
Revenue
$302,000
Gross profit
$302,000
Operating income
-$337.01M
Net income
-$308.32M
EBIT
-$305.27M
EBITDA
-$304.58M
Free cash flow
-$280.35M
Per share
Balance sheet
Liquidity
EPS
-$3.13
EPS diluted
-$3.13
Free cash flow per share
-$3.45
Book value per share
$7.42
Revenue per share
$0
TBVPS
$8.13
Total assets
$660.98M
Total liabilities
$56.51M
Debt
$20.69M
Equity
$604.47M
Working capital
$623.51M
Debt to equity
0.03
Current ratio
19.49
Quick ratio
18.88
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
-100,854.6%
Gross margin
100%
Net margin
-102,092.4%
Operating margin
-111,591.1%
Return on assets
-44.7%
Return on equity
-49.1%
Return on invested capital
-56.5%
Return on capital employed
-48.7%
Return on sales
-101,084.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRDN stock price
How has the Viridian Therapeutics stock price performed over time
Intraday
-3.05%
1 week
-9.03%
1 month
5.09%
1 year
-10.93%
YTD
-35.37%
QTD
-8.09%
Financial performance
How have Viridian Therapeutics's revenue and profit performed over time
Revenue
$302,000
Gross profit
$302,000
Operating income
-$337.01M
Net income
-$308.32M
Gross margin
100%
Net margin
-102,092.4%
The operating income has declined by 42% year-on-year and by 13% since the previous quarter
The net income has contracted by 41% YoY and by 14% from the previous quarter
Viridian Therapeutics's net margin has decreased by 35% YoY and by 14% QoQ
The operating margin has decreased by 35% YoY and by 13% QoQ
Price vs fundamentals
How does VRDN's price correlate with its fundamentals
Growth
What is Viridian Therapeutics's growth rate over time
Valuation
What is Viridian Therapeutics stock price valuation
P/E
N/A
P/B
1.67
P/S
3,337.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,031.11
Viridian Therapeutics's EPS has decreased by 8% YoY
The price to book (P/B) is 20% less than the 5-year quarterly average of 2.1 and 12% less than the last 4 quarters average of 1.9
The equity fell by 10% QoQ but it rose by 3.8% YoY
The P/S is 140% more than the 5-year quarterly average of 1391.5 but 16% less than the last 4 quarters average of 3957.0
VRDN's revenue is up by 4.9% YoY
Efficiency
How efficient is Viridian Therapeutics business performance
Viridian Therapeutics's return on sales has decreased by 35% YoY and by 14% QoQ
Viridian Therapeutics's return on invested capital has decreased by 14% QoQ but it has increased by 10% YoY
The company's return on equity fell by 13% QoQ but it rose by 9% YoY
The return on assets has declined by 13% since the previous quarter but it rose by 8% year-on-year
Dividends
What is VRDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRDN.
Financial health
How did Viridian Therapeutics financials performed over time
VRDN's quick ratio is up by 26% since the previous quarter but it is down by 20% year-on-year
VRDN's current ratio is up by 26% since the previous quarter but it is down by 19% year-on-year
Viridian Therapeutics's debt is 97% lower than its equity
The equity fell by 10% QoQ but it rose by 3.8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.